CE Disclosures and Faculty Information

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of gastrointestinal cancers.

  OVERVIEW OF ACTIVITY
  Given the prevalent nature of the disease, extensive resources are allocated to colorectal cancer (CRC) research and education. Of interest, however, although individually less frequently encountered, the collection of other “non-CRC” gastrointestinal (GI) cancers accounts for more per annum cancer-related deaths than those attributed to tumors of the colon and rectum combined. In addition to maintaining a sound understanding of the conventional but distinct treatment algorithms applicable to each subtype of non-CRC GI cancer, practicing oncologists must now rationally integrate targeted agents into their individualized therapeutic recommendations for the safe and effective clinical management of diseases they seldom encounter.

  These proceedings from a CME symposium held during the 2013 Gastrointestinal Cancers Symposium use the perspectives of renowned GI cancers experts to explore the self-described practice patterns of 25 clinical investigators and the supporting research database in a number of commonly encountered clinical situations. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers with the formulation of up-to-date clinical management strategies for various non-CRC GI cancers.

  LEARNING OBJECTIVES

  • Effectively integrate the evidence-based use of chemotherapy into the individualized management of advanced pancreatic cancer.
  • Communicate the benefits and risks of existing and emerging systemic interventions to patients with locally advanced or metastatic hepatocellular cancer.
  • Identify patients with GIST who are likely to benefit from adjuvant therapy, and determine treatment strategies for patients with imatinib-resistant disease.
  • Educate patients with gastric cancer about novel treatment approaches in the locally advanced and metastatic disease settings.
  • Identify the optimal sequencing of systemic therapies for patients with metastatic neuroendocrine tumors of the GI tract.
  • Counsel patients with cancers of the GI tract about participation in ongoing clinical trials.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

  
  CME credit is no longer available for this issue
  
  

  CREDIT DESIGNATION STATEMENT
  
  CME credit is no longer available for this issue
  
  

  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of a video component. The participant should watch the video.
  CME credit is no longer available for this issue
  
  

  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

  FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

  Charles S Fuchs, MD, MPH
  Director, Center for Gastrointestinal Cancer
  Dana-Farber/Harvard Cancer Center
  Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts

  Advisory Committee: Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech BioOncology, Genomic Health Inc, Pfizer Inc, Sanofi.

  Philip A Philip, MD, PhD, FRCP
  Professor of Oncology and Medicine
  Director of GI and Neuroendocrine Tumors
  Vice President of Medical Affairs
  Karmanos Cancer Institute
  Wayne State University
  Detroit, Michigan

  Advisory Committee: Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Sanofi; Contracted Research: Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Onyx Pharmaceuticals Inc; Speakers Bureau: Amgen Inc, Bayer HealthCare Pharmaceuticals, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Roche Laboratories Inc, Sanofi.

  Alan P Venook, MD
  Professor of Clinical Medicine
  University of California, San Francisco
  San Francisco, California

  Consulting Agreement: Sanofi; Contracted Research: Bayer HealthCare Pharmaceuticals, Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline, Onyx Pharmaceuticals Inc.

  Andrew X Zhu, MD, PhD
  Director, Liver Cancer Research
  Massachusetts General Hospital Cancer Center
  Associate Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts

  Advisory Committee: Abbott Laboratories, Bristol-Myers Squibb Company, Eisai Inc, Sanofi.

  Matthew Kulke, MD, MMSc
  Director, Program in Neuroendocrine and Carcinoid Tumors
  Dana-Farber/Brigham and Women’s Cancer Center
  Associate Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts

  Consulting Agreements: Novartis Pharmaceuticals Corporation, Pfizer Inc.

  MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly USA LLC, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

  RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

  This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Onyx Pharmaceuticals Inc, Regeneron Pharmaceuticals and Sanofi.

  Hardware/Software Requirements:
  
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
  Adobe Flash Player 10.2 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  A high-speed Internet connection